Literature DB >> 33764295

Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis.

Matt Stevenson1, Andrew Metry1, Michael Messenger2,3.   

Abstract

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019. At the time of writing (October 2020), the number of cases of COVID-19 had been approaching 38 million and more than 1 million deaths were attributable to it. SARS-CoV-2 appears to be highly transmissible and could rapidly spread in hospital wards.
OBJECTIVE: The work undertaken aimed to estimate the clinical effectiveness and cost-effectiveness of viral detection point-of-care tests for detecting SARS-CoV-2 compared with laboratory-based tests. A further objective was to assess occupancy levels in hospital areas, such as waiting bays, before allocation to an appropriate bay. PERSPECTIVE/
SETTING: The perspective was that of the UK NHS in 2020. The setting was a hypothetical hospital with an accident and emergency department.
METHODS: An individual patient model was constructed that simulated the spread of disease and mortality within the hospital and recorded occupancy levels. Thirty-two strategies involving different hypothetical SARS-CoV-2 tests were modelled. Recently published desirable and acceptable target product profiles for SARS-CoV-2 point-of-care tests were modelled. Incremental analyses were undertaken using both incremental cost-effectiveness ratios and net monetary benefits, and key patient outcomes, such as death and intensive care unit care, caused directly by COVID-19 were recorded.
RESULTS: A SARS-CoV-2 point-of-care test with a desirable target product profile appears to have a relatively small number of infections, a low occupancy level within the waiting bays, and a high net monetary benefit. However, if hospital laboratory testing can produce results in 6 hours, then the benefits of point-of-care tests may be reduced. The acceptable target product profiles performed less well and had lower net monetary benefits than both a laboratory-based test with a 24-hour turnaround time and strategies using data from currently available SARS-CoV-2 point-of-care tests. The desirable and acceptable point-of-care test target product profiles had lower requirement for patients to be in waiting bays before being allocated to an appropriate bay than laboratory-based tests, which may be of high importance in some hospitals. Tests that appeared more cost-effective also had better patient outcomes. LIMITATIONS: There is considerable uncertainty in the values for key parameters within the model, although calibration was undertaken in an attempt to mitigate this. The example hospital simulated will also not match those of decision-makers deciding on the clinical effectiveness and cost-effectiveness of introducing SARS-CoV-2 point-of-care tests. Given these limitations, the results should be taken as indicative rather than definitive, particularly cost-effectiveness results when the relative cost per SARS-CoV-2 point-of-care test is uncertain.
CONCLUSIONS: Should a SARS-CoV-2 point-of-care test with a desirable target product profile become available, this appears promising, particularly when the reduction on the requirements for waiting bays before allocation to a SARS-CoV-2-infected bay, or a non-SARS-CoV-2-infected bay, is considered. The results produced should be informative to decision-makers who can identify the results most pertinent to their specific circumstances. FUTURE WORK: More accurate results could be obtained when there is more certainty on the diagnostic accuracy of, and the reduction in time to test result associated with, SARS-CoV-2 point-of-care tests, and on the impact of these tests on occupancy of waiting bays and isolation bays. These parameters are currently uncertain. FUNDING: This report was commissioned by the National Institute for Health Research (NIHR) Evidence Synthesis programme as project number 132154. This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 21. See the NIHR Journals Library website for further project information.

Entities:  

Keywords:  COST-EFFECTIVENESS; COST–BENEFIT ANALYSIS; COVID-19; DIAGNOSTIC TESTS; POINT-OF-CARE SYSTEMS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Year:  2021        PMID: 33764295      PMCID: PMC8020197          DOI: 10.3310/hta25210

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  19 in total

1.  Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.

Authors:  A A Stinnett; J Mullahy
Journal:  Med Decis Making       Date:  1998 Apr-Jun       Impact factor: 2.583

2.  Covid-19: Do many people have pre-existing immunity?

Authors:  Peter Doshi
Journal:  BMJ       Date:  2020-09-17

3.  Temporal dynamics in viral shedding and transmissibility of COVID-19.

Authors:  Xi He; Eric H Y Lau; Peng Wu; Xilong Deng; Jian Wang; Xinxin Hao; Yiu Chung Lau; Jessica Y Wong; Yujuan Guan; Xinghua Tan; Xiaoneng Mo; Yanqing Chen; Baolin Liao; Weilie Chen; Fengyu Hu; Qing Zhang; Mingqiu Zhong; Yanrong Wu; Lingzhai Zhao; Fuchun Zhang; Benjamin J Cowling; Fang Li; Gabriel M Leung
Journal:  Nat Med       Date:  2020-04-15       Impact factor: 53.440

4.  Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople).

Authors:  B Carter; J T Collins; F Barlow-Pay; F Rickard; E Bruce; A Verduri; T J Quinn; E Mitchell; A Price; A Vilches-Moraga; M J Stechman; R Short; A Einarsson; P Braude; S Moug; P K Myint; J Hewitt; L Pearce; K McCarthy
Journal:  J Hosp Infect       Date:  2020-07-21       Impact factor: 3.926

5.  Characterisation of 22445 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study.

Authors:  Steve Goodacre; Ben Thomas; Ellen Lee; Laura Sutton; Amanda Loban; Simon Waterhouse; Richard Simmonds; Katie Biggs; Carl Marincowitz; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

6.  Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study.

Authors:  Nathan J Brendish; Stephen Poole; Vasanth V Naidu; Christopher T Mansbridge; Nicholas J Norton; Helen Wheeler; Laura Presland; Stephen Kidd; Nicholas J Cortes; Florina Borca; Hang Phan; Gavin Babbage; Benoit Visseaux; Sean Ewings; Tristan W Clark
Journal:  Lancet Respir Med       Date:  2020-10-08       Impact factor: 30.700

7.  Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.

Authors:  Jacqueline Dinnes; Jonathan J Deeks; Ada Adriano; Sarah Berhane; Clare Davenport; Sabine Dittrich; Devy Emperador; Yemisi Takwoingi; Jane Cunningham; Sophie Beese; Janine Dretzke; Lavinia Ferrante di Ruffano; Isobel M Harris; Malcolm J Price; Sian Taylor-Phillips; Lotty Hooft; Mariska Mg Leeflang; René Spijker; Ann Van den Bruel
Journal:  Cochrane Database Syst Rev       Date:  2020-08-26

8.  Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis.

Authors:  Hyungjin Kim; Hyunsook Hong; Soon Ho Yoon
Journal:  Radiology       Date:  2020-04-17       Impact factor: 11.105

9.  Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study.

Authors:  Dami A Collier; Sonny M Assennato; Ben Warne; Nyarie Sithole; Katherine Sharrocks; Allyson Ritchie; Pooja Ravji; Matthew Routledge; Dominic Sparkes; Jordan Skittrall; Anna Smielewska; Isobel Ramsey; Neha Goel; Martin Curran; David Enoch; Rhys Tassell; Michelle Lineham; Devan Vaghela; Clare Leong; Hoi Ping Mok; John Bradley; Kenneth G C Smith; Vivienne Mendoza; Nikos Demiris; Martin Besser; Gordon Dougan; Paul J Lehner; Mark J Siedner; Hongyi Zhang; Claire S Waddington; Helen Lee; Ravindra K Gupta
Journal:  Cell Rep Med       Date:  2020-07-15
View more
  7 in total

1.  Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.

Authors:  Lihui Zhou; Wenxin Yan; Shu Li; Hongxi Yang; Xinyu Zhang; Wenli Lu; Jue Liu; Yaogang Wang
Journal:  J Glob Health       Date:  2022-06-15       Impact factor: 7.664

2.  Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis.

Authors:  Matt Stevenson; Andrew Metry; Michael Messenger
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

3.  COVID-19 rapid diagnostics: practice review.

Authors:  Charles Reynard; Joy A Allen; Bethany Shinkins; Graham Prestwich; Johnathan Goves; Kerrie Davies; Richard Body
Journal:  Emerg Med J       Date:  2021-11-05       Impact factor: 2.740

4.  Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations.

Authors:  Jamie Elvidge; Ashley Summerfield; David Nicholls; Dalia Dawoud
Journal:  Value Health       Date:  2022-02-16       Impact factor: 5.101

5.  COVID-19 Health Economics: Looking Back and Scoping the Future.

Authors:  Maarten J Postma; Jagpreet Chhatwal
Journal:  Value Health       Date:  2022-04-04       Impact factor: 5.101

Review 6.  Economic evaluation of laboratory diagnostic test types in Covid-19 epidemic: A systematic review.

Authors:  Zeinab Dolatshahi; Shahin Nargesi; Jamil Sadeghifar; Fateme Mezginejad; Abdosaleh Jafari; Mohammad Bazyar; Sobhan Ghafourian; Nadia Sani'ee
Journal:  Int J Surg       Date:  2022-08-17       Impact factor: 13.400

7.  COVID-19 rapid molecular point-of-care testing is effective and cost-beneficial for the acute care of trauma patients.

Authors:  Josef Stolberg-Stolberg; Elena Jacob; Joachim Kuehn; Marc Hennies; Wali Hafezi; Moritz Freistuehler; Jeanette Koeppe; Alex W Friedrich; J Christoph Katthagen; Michael J Raschke
Journal:  Eur J Trauma Emerg Surg       Date:  2022-09-06       Impact factor: 2.374

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.